Skip to main content

Table 2 Comparison of laboratory results between the progression group and the non-progression group at first /follow-up visits

From: Insulin resistance predicts progression of de novo atherosclerotic plaques in patients with coronary heart disease: a one-year follow-up study

Variable
Initial/ follow-up visit
Progression Group (n = 198) Non-progression Group (n = 168) p value
Fasting glucose (mmol/L) 6.15 ± 1.81 5.49 ± 1.25 <0.001
7.84 ± 1.80 5.30 ± 1.22 0.005
OGTT (mmol/L) 10.09 ± 4.17 8.65 ± 3.41 <0.001
9.68 ± 3.79 8.47 ± 3.38 0.002
Fasting insulin (mU/L) 13.50 ± 26.58 12.57 ± 27.04 0.010
14.43 ± 19.01 17.10 ± 60.81 0.002
Postprandial insulin (mU/L) 78.31 ± 117.74 62.43 ± 65.86 0.388
80.27 ± 71.31 88.35 ± 107.35 0.868
Bennett index 1.79 ± 0.65 0.41 ± 0.56 <0.001
  0.95 ± 0.84 0.67 ± 0.95 <0.001
HbA1c (%) 6.73 ± 1.40 6.24 ± 0.98 0.001
6.79 ± 1.53 6.07 ± 0.78 <0.001
hsCRP (mg/L) 9.28 ± 13.56 13.34 ± 22.51 0.600
6.55 ± 12.01 2.68 ± 4.14 0.048
BUN (mmol/L) 5.44 ± 1.59 5.45 ± 1.50 0.941
6.06 ± 1.90 5.70 ± 1.48 0.623
Creatinine (umol/L) 84.47 ± 18.34 89.90 ± 36.51 0.671
93.11 ± 23.46 87.28 ± 18.87 0.585
Urine acid (umol/L) 339.83 ± 76.41 339.30 ± 85.77 0.878
358.38 ± 81.25 362.80 ± 79.00 0.966
Urine Ma/Cr 12.12 ± 49.70 3.65 ± 18.74 0.011
16.00 ± 69.94 2.09 ± 3.14 0.366
GFR (ml/min) 80.16 ± 25.46 76.62 ± 28.98 0.345
73.52 ± 25.48 71.55 ± 23.33 0.049
Serum triglyceride (mmol/L) 2.13 ± 1.72 1.86 ± 2.01 0.072
1.76 ± 1.34 1.65 ± 1.50 0.207
Serum cholesterol (mmol/L) 4.58 ± 1.22 4.18 ± 1.09 0.103
2.08 ± 0.76 2.05 ± 0.78 0.412
HDL (mmol/L) 1.05 ± 0.23 1.05 ± 0.26 0.706
1.06 ± 0.26 1.14 ± 0.26 0.246
LDL (mmol/L) 2.81 ± 0.96 2.45 ± 0.84 0.118
2.08 ± 0.76 2.05 ± 0.78 0.412
Lpa (mmol/L) 0.21 ± 0.21 0.20 ± 0.18 0.941
0.21 ± 0.17 0.30 ± 0.49 0.317
ApoA (mmol/L) 1.13 ± 0.22 1.12 ± 0.20 0.764
1.11 ± 0.22 1.12 ± 0.29 0.738
ApoB (mmol/L) 0.93 ± 0.28 0.87 ± 0.26 0.342
0.80 ± 0.25 0.77 ± 0.23 0.225
Ejection Fraction 62.50 ± 9.06 64.01 ± 6.86 0.331
  62.62 ± 8.38 62.62 ± 8.20 0.153